Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway

BACKGROUND: t(8;21) acute myeloid leukemia (AML) is a highly heterogenous hematological malignancy. Histone deacetylases inhibitors (HDACi) are a group of small-molecule compounds with extensive anti-tumor activity. Chidamide (CS055) is a selective HDACi independently developed by China. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Lv, Na, Zhou, Lei, Li, Yan, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799002/
https://www.ncbi.nlm.nih.gov/pubmed/35117428
http://dx.doi.org/10.21037/tcr.2019.12.07

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799002/
https://www.ncbi.nlm.nih.gov/pubmed/35117428
http://dx.doi.org/10.21037/tcr.2019.12.07

Ejemplares similares